• Revvity first-quarter 2026 earnings call drew CEO, President and Director Prahlad R. Singh, Senior VP and CFO Maxwell Krakowiak, Senior VP of Investor Relations and Head of ESG Stephen Barr Willoughby, with analysts from Baird, TD Cowen, BofA Securities, Citi, Leerink Partners, Jefferies, Evercore ISI.
• Plan set to divest China immunodiagnostics business, about 6% of prior-year revenue; letter of intent signed with local management-led buyer group; definitive agreement targeted within two months; closing expected by end of 2027; minority interest to be retained.
• Updated 2026 pro forma outlook excludes that business: organic growth 3%-4%, adjusted operating margin about 28.4%, adjusted EPS USD 5.20-5.30; total revenue USD 2.81 billion-USD 2.84 billion; EPS outlook excludes any proceeds since deal expected to close in 2027.
• First-quarter results: revenue USD 711 million, organic growth 3%, adjusted operating margin 23.6%, adjusted EPS USD 1.06; pro forma view excluding China immunodiagnostics: revenue USD 687 million, organic growth 6%, adjusted operating margin 24%, adjusted EPS USD 1.04.
• Management flagged improving end-market signals, with reproductive health up low double digits on newborn screening strength, instrument placements, Genomics England volumes slightly ahead of plan; software APV growth stayed double digits, with organic growth expected down about 20% in Q2 on tough comps, then high-teens growth in H2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.